The Pharmaceutical Market: Malaysia - Market Research Reports

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/45270

The Pharmaceutical Market: Malaysia

Description:

THE PHARMACEUTICAL MARKET: MALAYSIA - REVIEW

The macroenvironment will be defined by an increase in GDP and population during the forecast period. Politically, the government aims to reduce its fiscal deficit in 2011, following a recent period of fiscal stimulus and loose monetary policy. Economically, Malaysia will be the ninth largest economy in the Asia Pacific region covered by Espicom in 2016. In terms of GDP per capita, Malaysia will rank eighth. Legally, Malaysia remains on the US Trade Representative’s (USTR) Watch List in 2011, despite the government strengthening its IPR protection and enforcement. Demographically, the population is estimated to have a high growth rate. By 2016, the EIU projects that the population of Malaysia will be the 11th largest in the Asia Pacific region. The elderly population is expected to grow in the forecast period. Malaysia has a largely young population, with those aged between 0-14 years old making up nearly a third of the total.

The Malaysian pharmaceutical market is small and relies heavily on the import of medicaments. Espicom projects the market to grow at a healthy CAGR in the forecast period. However, it will remain as the fifth smallest pharmaceutical market in the Asia Pacific region in size terms by 2016. There are around 250 Malaysian pharmaceutical manufacturers licensed by the Drug Control Authority, although over two-thirds of these are traditional medicine manufacturers. There is little multinational manufacturing activity in the country due to strict regulations, although these may be relaxed in the future. Ranbaxy and GSK are the only examples of large global multinational companies that have manufacturing operations in the country. Malaysia is heavily dependent on the imports of retail medicaments, which represent over three-quarters of total imports. As most pharmaceutical manufacturing is for local consumption, the balance of pharmaceutical trade will remain considerably negative, and the deficit is likely to increase in the forecast period.

The government has identified biotechnology as one of the core technologies to accelerate the transformation of Malaysia into a knowledge-based economy and an industrialised nation by year 2020. The Malaysian Biotechnology Corporation (BiotechCorp) is the leading agency responsible for the co-ordinated implementation of the National Biotechnology Policy (NBP). The most important Malaysian biologic manufacturers include Bioven, CCM Duopharma, Inno Biologics and Ninebio. The National Pharmaceutical Control Bureau (NPCB) has adopted the Guidance Document and Guidelines for the Registration of Biosimilars, making Malaysia only the second country, after Australia, in the Asia Pacific region to adopt regulations for biosimilar registration. There have been a number of competitive strategies completed over the last 12 months: Agila Specialities has agreed to establish a biopharmaceuticals facility at Bio-XCell park; US-based Viropro has acquired Alpha Biologics; and Indian-based Avesthage, in partnership with Inno Biologics, has manufactured clinical grade darbepoetin alfa, its biosimilar version of Amgen’s Aranesp.

ENHANCED STRATEGIC INTELLIGENCE

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

Contents:

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections

MACROENVIRONMENT
Political, economic, legal and demographic analysis

EPIDEMIOLOGY
Disease burden and prevalence

HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce

REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET ANALYSIS
Projections, product development, manufacturing and trade

COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis

DIRECTORY

METHODOLOGY & SOURCES

Companies Mentioned

- Pharmaniaga - Zuellig Pharma - Apex Healthcare Berhad

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/45270

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed 13/02/2012 08:04:23

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.


Product Name:
The Pharmaceutical Market: Malaysia
Web Address:
http://www.researchandmarkets.com/reports/45270
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (Online Access) - Enterprisewide		€5,050.00
Electronic (PDF) - Enterprisewide		€5,050.00
Electronic (Online Access) - Single User		€775.00
Hard Copy		€775.00 + EUR€ 50.00 Shipping/Handling *
Electronic (PDF) - Single User		€775.00

* Shipping/Handling is only charged once per order.

Contact information
Please enter all the information below in BLOCK CAPITALS.


	First Name:	Last Name:
	Email Address:
	Job Title:
	Organisation:
	Address:
	City:
	Postal/Zip Code:
	Country:
	Phone Number:
	Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed 13/02/2012 08:04:23

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

	American Express
	Diners Club
	Master Card
	Visa


Cardholder's Name:

Cardholder's Signature:

Expiry Date:	/

Card Number:

CVV Security Code:

Issue Date:	/ (Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:


Account number:	83313083
Sort code:	98-53-30
Swift code:	ULSBIE2D
IBAN number:	IE78ULSB98533083313083
Bank Address:	Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:
	Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)